Fairmont Hotel Vancouver Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2019



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Vaccines (L2)


Organizer(s) Lélia Delamarre, Robert A. Seder and Nina Bhardwaj
January 20—24, 2019
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Discounted Abstract Deadline: Oct 16, 2018
Abstract Deadline: Oct 24, 2018
Scholarship Deadline: Oct 16, 2018
Discounted Registration Deadline: Nov 27, 2018

Organized in collaboration with Cancer Research UK

Sponsored by BioLegend, Inc., Genentech, Inc. and Pfizer Inc.

Summary of Meeting:
The success of immunotherapy in the treatment of cancer patients has proved the long-standing hypothesis that endogenous adaptive immune responses against the tumor can be harnessed to mediate protection by immune checkpoint blockade. This approach has shown impressive control of disease and improved survival in up to 50% of patients with certain tumors. Genetic and immune analysis of human cancers suggests that one mechanism of resistance to immune checkpoint blockade may be due to lack of tumor-specific T cells. In principle, vaccines have the potential to overcome this defect by either expanding low-level existing tumor-specific T cell responses or priming tumor-specific T cells. Recent advances in next-generation sequencing have improved our understanding of defining cancer antigens. Application of this will require vaccine delivery approaches that can induce potent and broad T cell immunity in an efficient manner for personalized therapy. This Keystone Symposia conference will highlight recent insights in the characterization of immunogenic cancer antigens, the biology and underlying mechanisms of T cell priming, and the development of novel approaches designed to expand T cell responses. Part of the meeting will also be devoted to the development of technologies to monitor T cell responses in response to immune interventions.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, January 20 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, January 24 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, January 25 in order to fully experience the meeting.

SUNDAY, JANUARY 20

4:00—8:00 PM
Arrival and Registration

Pacific Ballroom Foyer
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Pacific Ballroom Foyer

MONDAY, JANUARY 21

7:30—8:30 AM
Breakfast

Vancouver Island/Waddington
8:30—10:00 AM
Welcome and Keynote Session
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
* Lélia Delamarre, Genentech, Inc., USA

* Robert A. Seder, NIAID, National Institutes of Health, USA

* Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA

Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Cancer Vaccines: Overview

Ira Mellman, Genentech, Inc., USA
The Mechanistic Basis of Cancer Immunotherapy

Coffee Break

10:20 AM—12:30 PM
Identification of Mutated Neoantigens
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
* Glenn Dranoff, Novartis Institutes for BioMedical Research, USA

Timothy A. Chan, Memorial Sloan Kettering Cancer Center, USA
Mutations and Neoantigens in Cancer Immunotherapy

Karin U. Jooss, Gritstone Oncology, USA
Driving CD8+ T Cell Responses to Mutational Neoantigens in Tumors - Harnessing Immunogenic Viral Vectors

Lélia Delamarre, Genentech, Inc., USA
Determinants of Cancer Neoantigen Immunogenicity

Binbin Chen, Stanford Medical School, USA
Short Talk: MARIA: Deep Neural Network Predicting HLA Class II Antigen Presentation for Personalized Cancer Vaccines

Lisa McNeil, Genocea Biosciences, USA
Short Talk: ATLAS™ Identifies Stimulatory and Inhibitory Neoantigens with Opposing Effects in a Murine Challenge Model

12:30—5:00 PM
On Own for Lunch

12:30—1:00 PM
Poster Setup

Pacific Ballroom
1:00—10:00 PM
Poster Viewing

Pacific Ballroom
2:30—4:30 PM
Workshop 1: Cancer Antigens and Immune Monitoring

Pacific Ballroom
Samuel J. Landry, Tulane University Health Sciences Center, USA
CD4+ Epitope Prediction Limited by Analysis of Antigen Conformational Flexibility

* Aude-Helene Capietto, Genentech, Inc., USA
Characterization of the Immunogenic Determinants of Tumor Neoantigens Improves their Identification

Cansu Cimen Bozkus, Icahn School of Medicine at Mount Sinai, USA
Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms

Russell Kent Pachynski, Washington University in St. Louis, USA
A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/Ipilimumab and Prostvac in Metastatic Hormone-Sensitive Prostate Cancer

Brandon Coder, Advaxis, USA
Neoantigen Prioritization for Use in a Listeria Monocytogenes Cancer Vaccine

Ghislain Bonamy, immunoSCAPE, Singapore
Leveraging the Multi-Parametric Profiling Capacity of Mass Cytometry to Query the Specificity of Tumor-Infiltrating T-Cells

4:30—5:00 PM
Coffee Available

Pacific Ballroom Foyer
5:00—7:00 PM
Other Cancer Antigens
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
* Lélia Delamarre, Genentech, Inc., USA

Stephen B. Baylin, Johns Hopkins University School of Medicine, USA
Immunogenicity of Transposable Elements in Cancer – Relevance to Epigenetic Therapy

Victor H. Engelhard, University of Virginia, USA
Post-Translationally Modified Cancer Neoantigens

Cornelia Liu Trimble, Johns Hopkins University School of Medicine, USA
Targeting HPV Antigens by Vaccination

Haiyin Chen, Genentech, Inc., USA
Short Talk: Transposable Element Expression in Tumors Is Associated with Immune Infiltrate and Increased Antigenicity

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Vancouver Island/Waddington
7:30—10:00 PM
Poster Session 1

Pacific Ballroom

TUESDAY, JANUARY 22

7:30—8:30 AM
Breakfast

Vancouver Island/Waddington
8:00—8:30 AM
Poster Setup

Pacific Ballroom
8:30 AM—5:00 PM
Poster Viewing

Pacific Ballroom
8:30—11:30 AM
Priming T Cells
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
* Sebastian Amigorena, Institut Curie, France

Rafi Ahmed, Emory University School of Medicine, USA
T Cell Exhaustion and PD-1 Immunotherapy

E. John Wherry, University of Pennsylvania, USA
The Developmental Program of Exhausted T Cells

Coffee Break

Pedro Romero, University of Lausanne, Switzerland
Programming T Cell Memory for Immunotherapy of Cancer

David B. Masopust, University of Minnesota, USA
Repurposing Antiviral T Cells to Fight Tumors

John P. Finnigan, Icahn School of Medicine at Mount Sinai, USA
Short Talk: Molecular and Cellular Properties of Neoantigen-Specific CD8+ T Cells Interacting with Melanoma in situ

Jared Klarquist, University of Colorado Denver, USA
Short Talk: Vaccine-Elicited T Cells Expand and Function Independently of Aerobic Glycolysis: Implications for Therapeutic Cancer Vaccines

11:30 AM—12:30 PM
Lunch

Vancouver Island/Waddington
12:00—2:30 PM
Poster Session 2

Pacific Ballroom
2:30—4:30 PM
Workshop 2: Vaccine Platforms

Pacific Ballroom
* Karin Loré, Karolinska Institutet, Sweden

Jaehak Oh, Genentech, Inc., USA
RNA-Lipoplex Vaccine Is Presented on MHCI and MHCII Molecules of Differential Dendritic Cell Subsets in Spleen

Yanling Xiao, Netherlands Cancer Institute, Netherlands
Antigen Cross-Presentation and T-Cell Priming Ability of Human Dendritic Cells Generated in vitro from a Newly Discovered Oligopotent Progenitor of Granulocytes, Macrophages, Osteoclasts and Dendritic Cells

Faezzah Baharom, National Institutes of Health, USA
Route, Dose and Agonist Potency Influence the Induction of TCF1+ Neoantigen-Specific CD8 T Cells by Peptide-TLR7/8 Agonist Nanoparticle Vaccine

Anna Morena D'Alise, Nouscom Srl, Italy
Novel Adenovector Vaccine Targeting Multiple Neoantigens Eeradicates Large Tumors in Mice in Combination with Checkpoint Blockade

Robert Petit, Advaxis Inc., USA
Magnitude of Anti-PSA T Cell Response Is Associated with Antigen Spreading and Slowing in PSA and PAP Velocity

Alessia Melacarne, Humanitas University, Italy
Antigens Released by Salmonella-Infected Tumor Cells as a Novel Vaccine Platform

Aymen Al-shamkhani, University of Southampton, UK
The Effects of Akt/Protein Kinase B on Effector and Memory CD8 T Cell Differentiation Revealed by Single Cell RNA-Seq

4:30—5:00 PM
Coffee Available

Pacific Ballroom Foyer
5:00—7:00 PM
Antigen-Presenting Cells
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
* Ira Mellman, Genentech, Inc., USA

Karin Loré, Karolinska Institutet, Sweden
Understanding Innate Immune Mechanisms Dictating Vaccine Responses

Sebastian Amigorena, Institut Curie, France
Dendritic Cell Biology

Marc Y. Dalod, Centre National de la Recherche Scientifique, France
Deciphering the Role of cDC1 in Anti-Tumor Immunity

Zwi N. Berneman, Antwerp University Hospital, Belgium
Short Talk: Vaccination of Cancer Patients with WT1 mRNA-Electroporated Dendritic Cells: Correlation of Clinical Effect and Overall Survival with T-Cell Response

Matthew G. Booty, SQZ Biotechnologies, USA
Short Talk: SQZ'ing Cells to Engineer a New Generation of Cancer Vaccines

7:00 PM
On Own for Dinner


WEDNESDAY, JANUARY 23

7:30—8:30 AM
Breakfast

Vancouver Island/Waddington
8:30—11:30 AM
Novel Cancer Vaccine Platforms I
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
* Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA

David B. Weiner, Wistar Institute, USA
DNA-Based Vaccines

John C. Bell, Ottawa Hospital Research Institute, Canada
Virus-Based Vaccines

Coffee Break

Ugur Sahin, BioNTech AG, Germany
RNA-Based Vaccines

Robert A. Seder, NIAID, National Institutes of Health, USA
Peptide-TLR 7/8 Agonist Vaccines Chemically Programmed to Enhance the Magnitude, Quality and Breadth of Neoantigen CD8 T Cell Responses

Christian J. Maine, Synthetic Genomics, USA
Short Talk: Self-Amplifying RNA Polytope Vaccines Can Elicit Anti-Tumor T Cell Responses Against Neoantigens for Cancer Immunotherapy

11:30 AM—5:00 PM
On Own for Lunch

4:30—5:00 PM
Coffee Available

Pacific Ballroom Foyer
5:00—7:00 PM
Novel Cancer Vaccine Platforms II
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
* Robert A. Seder, NIAID, National Institutes of Health, USA

Catherine Ju-Ying Wu, Dana-Farber Cancer Institute, USA
Building Better Personal Cancer Vaccines

Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA
DC Targeted Vaccines

Joshua Tobias, Medical University of Vienna, Austria
Short Talk: A Paradigm Change in Cancer Immunotherapy: Combined B Cell Epitope Peptides of Her-2/neu and Immune Checkpoint Inhibitors for Active Immunization

Mubeen M. Mosaheb, Duke University, USA
Short Talk: A Poliovirus-Based Recombinant Vector Activates Antigen-Presenting Cells and Primes Anti-Tumor T Cell Immunity

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Vancouver Island/Waddington

THURSDAY, JANUARY 24

7:30—8:30 AM
Breakfast

Vancouver Island/Waddington
8:30—11:30 AM
Tumor Microenvironment and Combination Therapies
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
* Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, USA

Joshua D. Brody, Icahn School of Medicine at Mount Sinai, USA
In situ Vaccination for Cancer

Shannon J. Turley, Genentech, Inc., USA
TGFbeta in Cancer

Coffee Break

Thomas Gajewski, University of Chicago, USA
Downstream Regulation at the Level of the Tumor Microenvironment

Darrell J. Irvine, Massachusetts Institute of Technology, USA
Combination Therapies Inducing a Self-Sustaining Vaccinal Cycle

Linda Hammerich, Icahn School of Medicine at Mount Sinai, USA
Short Talk: In situ Vaccination Improves Efficacy of PD-1 Blockade in Unresponsive Lymphoma Tumors via Induction of Antigen Cross-Presentation by Dendritic Cells

Bin Liu, University of California, Los Angeles, USA
Short Talk: Combination of in situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) and Anti-PD1 for Non-Small Cell Lung Cancer (NSCLC)

11:30 AM—5:00 PM
On Own for Lunch

2:30—4:30 PM
Workshop 3: Combination Therapies

Pacific Ballroom
* Joshua D. Brody, Icahn School of Medicine at Mount Sinai, USA

Selma Bekri, Icahn School of Medicine at Mount Sinai, USA
Mechanisms of CD4 T Cell Tumor Immunity in a Preclinical Model of a Neoantigen Vaccine for Multiple Myeloma

Elham Beyranvand Nejad, Leiden University Medical Center, Netherlands
Non-Curative Immunotherapy Drives the Development of Immune-Deserted Recurrences

Rosmely Hernandez, University of Miami Miller School of Medicine, USA
IL-2-Dependent Amplification of T Effector and Memory Responses to Promote Anti-Tumor Immunity

Zhen Zeng, University of Queensland, Australia
The Involvement of IFN-γ and CXCR3 in the CD8+ T-Cell-Mediated Regression of Squamous Cell Carcinoma

Ramin Salehi-Rad, University of California, Los Angeles, USA
Tumor Vaccination with CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Checkpoint Blockade in Murine Models of NSCLC with Varying Mutational Load

4:30—5:00 PM
Coffee Available

Pacific Ballroom Foyer
5:00—6:45 PM
Immune Monitoring of T Cells
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands
Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers

Sjoerd H. van der Burg, Leiden University Medical Center, Netherlands
NKG2A Blockade Potentiates CD8+ T-Cell Immunity Induced by Therapeutic Cancer Vaccines

* Evan W. Newell, Fred Hutchinson Cancer Research Center, USA
Asking T Cells About What They See in Cancer

Mark Klinger, Adaptive Biotechnologies, USA
Short Talk: Optimization of Cancer Vaccine Development by using Multiplexed Identification of T-Cell Receptor Antigen Specificity (MIRA)

6:45—7:00 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Pacific Ballroom
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pacific Ballroom
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Pacific Ballroom

FRIDAY, JANUARY 25

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

BioLegend, Inc. Organized in collaboration with Cancer Research UK
Genentech, Inc. Pfizer Inc.

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health
National Center for Advancing Translational Sciences (NCATS)

Grant No. 1R13CA236283-01

Funding for this conference was made possible (in part) by 1R13CA236283-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

American Society of Gene & Cell Therapy (ASGCT) Genocea Biosciences

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genentech, Inc.


Novartis Institutes for BioMedical Research


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179